IPO - Profile


We are a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions). We have pioneered our proprietary Lapiplasty 3D Bunion Correction System—a combination of novel instruments, implants and surgical methods designed to improve the inconsistent clinical outcomes of traditional approaches to bunion surgery. Although bunions are deformities typically caused by an unstable joint in the middle of the foot that leads to a three-dimensional (3D) misalignment in the foot’s anatomical structure, the majority of traditional surgical approaches focus on More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 11,250,000 Positive High 45.5%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • Grant Thornton LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 22 Apr, 2021

Offer 23 Apr, 2021

Look Ahead

Lock Up Expiry Oct 23, 2021

IPO Terms

Offer Price $17.00
Offer Size 11M

Market Sentiments

Stock Price